St. Louis, MO – 18 August 2015 – BacterioScan, Inc. and collaborators from the Institute of Medical Microbiology of the University Hospital Münster, (Münster, Germany) announce that the German Society of Hygiene and Microbiology (DGHM) has accepted research for publication during the society’s 67th Annual Meeting (September 27 – 30, 2015) in Münster. The researchers showed that the real-time laser-scattering method using the BacterioScan 216R device possesses potency for rapid phenotypic detection of methicillin-resistant Staphylococcus aureus (MRSA).
Over the last five decades, staphylococci have become increasingly resistant to commonly used penicillin-related medications. These bacteria are known as MRSA and can cause life threatening infections. The rapid differentiation between methicillin-susceptible (MSSA) and methicillin-resistant (MRSA) Staphylococcus aureus isolates is crucial for the initiation of an appropriate and targeted antimicrobial therapy.
“Rapid detection and phenotypic differentiation of MRSA and MSSA is an important step towards improving the ability to detect septicemia, a life threatening blood infection, improve patient care and reducing healthcare costs” said BacterioScan’s President and CEO, Dana Marshall.
BacterioScan’s instruments are at work in several world-class hospitals and universities globally to rapidly detect microorganism growth, antibiotic resistance and susceptibility in various types of bacterial infections. Recent publications include research from the US Centers for Disease Control and Prevention (CDC), St. Jude’s Children’s Research Center and Rambam Hospital (Haifa, Israel) and others, demonstrate BacterioScan’s technology can reduce the time for selection of effective antibiotic therapy from 30 or more hours to less than 3 hours, offering a potential breakthrough in addressing the worldwide urgent challenge of antibiotic resistance.
About BacterioScan, Inc.
BacterioScan, Inc. is an in-vitro diagnostics (IVD) company focused on the rapid detection and real-time quantification of bacteria in fluid using optical measurements. BacterioScan’s instruments can rapidly detect bacterial growth, determine if it is resistant to a range of antibiotics, and provide clinicians with patient-specific guidance on the most rapid and cost-effective treatment plan. BacterioScan’s first medical device product, the 216Dx, is a compact, simple, and low-cost system for rapid detection of Urinary Tract Infection (UTI) for use in clinical microbiology labs. BacterioScan, Inc. is a privately held global corporation, with headquarters in St. Louis, Missouri.
Rhonda Soest, RN
BacterioScan Inc.
4041 Forest Park Ave
St. Louis, MO 63108
Cell 636 795 4923
Office 315 615 6322
Www.bacterioscan.com
@bacterioscan
Rhonda Soest, RN
BacterioScan
Office 314 615 6322
Cell 636 795 4923
4041 Forest Park Ave
St. Louis, MO 63108
www.BacterioScan.com
Help employers find you! Check out all the jobs and post your resume.
